Each year the European Association of Urology (EAU) produce a document based on the most recent evidence on the diagnosis, therapy, and follow-up of testicular cancer (TC).
To represent a summarised version of the EAU guidelines on TC for 2023 with a focus on key changes in the 2023 update.
A multidisciplinary panel of TC experts, comprising urologists, medical and radiation oncologists, and pathologists, reviewed the results from a structured literature search to compile the guidelines document. Each recommendation in the guidelines was assigned a strength rating.
For the 2023 EAU guidelines on TC, a review and restructure were undertaken. The key changes incorporated in the 2023 update include: new supporting text regarding venous thromboembolism prophylaxis in males with metastatic germ cell tumours receiving chemotherapy; quality of life after treatment; an update of the histological classifications and inclusion of the World Health Organization 2022 pathological classification; inclusion of the revalidation of the 1997 International Germ Cell Cancer Collaborative Group prognostic risk factors; and a new section covering oncology treatment protocols.
The 2023 version of the EAU guidelines on TC include the highest available scientific evidence to standardise the management of TC. Better stratification and optimisation of treatment modalities will continue to improve the high survival rates for patients with TC.
This article presents a summary of the European Association of Urology guidelines on testicular cancer published in 2023 and includes the latest recommendations for management of this disease. The guidelines are a valuable resource that may help patients in understanding treatment recommendations.
European urology. 2023 May 12 [Epub ahead of print]
Anna Patrikidou, Walter Cazzaniga, Daniel Berney, Joost Boormans, Isabel de Angst, Domenico Di Nardo, Christian Fankhauser, Stefanie Fischer, Carmen Gravina, Hendrik Gremmels, Axel Heidenreich, Florian Janisch, Ricardo Leão, Nicola Nicolai, Christoph Oing, Jan Oldenburg, Robert Shepherd, Torgrim Tandstad, David Nicol
Department of Oncology, Institut Gustave Roussy, Villejuif, France., Department of Urology, The Royal Marsden NHS Foundation Trust, London, UK., Barts Cancer Institute, Queen Mary University of London, London, UK., Department of Urology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands., Patient Representative, European Association of Urology Guidelines Office, Arnhem, The Netherlands., Department of Urology, Luzerner Kantonsspital, Luzern, Switzerland., Department of Medical Oncology and Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland., Department of Urology, Sant'Andrea Hospital-Sapienza University, Rome, Italy., Department of Urology, Uniklinik Koln, Cologne, Germany., Department of Urology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany., Department of Urology, Faculty of Medicine, University of Coimbra, Clinical Academic Center of Coimbra, Coimbra, Portugal., Department of Surgery, Urology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Department of Oncology, Freeman Hospital NHS Foundation Trust, London, UK., Department of Oncology, Akershus University Hospital, Lorenskog, Norway., Department of Oncology, The Cancer Clinic, St. Olav's University Hospital, Trondheim, Norway., Department of Urology, The Royal Marsden NHS Foundation Trust, London, UK; Institute of Cancer research, London, UK. Electronic address: .